Therapeutic Antibody Discovery Services

Our integrated and streamlined processes ensure rapid development. Sequence identification via phage display takes only 2-3 weeks, and expression in rAbs using our XtenCHO™ cell line adds just 2 more weeks. This means you can have recombinant antibodies ready for testing in just 4-5 weeks. If only sequences are needed, it takes just 2-3 weeks. Even with antigen production, the total time is under 2 months. For catalog antigens, the total time remains 4-5 weeks.

Our comprehensive services include:

• Target Discovery and Validation: Efficient gene synthesis, high-quality peptide synthesis, and reliable protein production.
• Lead Generation: Hybridoma development, phage display, and single B cell isolation.
• Antibody Engineering: Humanization, affinity maturation, bispecific antibody development, and antibody drug conjugates.
• Bioproduction: Recombinant antibody production, stable cell line development, and high throughput antibody production.
• Bioproduction: Recombinant antibody production, stable cell line development, and high throughput antibody production.

Our process is fully tailored to your needs, allowing you to select specific services or engage in the entire development pipeline based on your project’s requirements.

Therapeutic antibody discovery is the process of identifying and developing antibodies that can be used as treatments for various diseases. This process includes several stages: target selection, lead generation, antibody engineering, and bioproduction. Each stage involves specific techniques and technologies to ensure the antibodies are effective and safe for therapeutic use.

We ensure quality through state-of-the-art equipment, proprietary innovations like our XtenCHO™ cell line, and a milestone-driven approach with Go/No Go points. This approach allows us to maintain high standards at each stage of development, ensuring the reliability and efficacy of the antibodies produced.

The timeline varies depending on the project’s complexity. However, our integrated and streamlined processes significantly reduce development time, allowing for quicker progression from target selection to clinical candidate.

Antibody therapeutic drugs are biologic medications that use monoclonal antibodies to target specific proteins or cells. These drugs are designed to interfere with disease processes, such as blocking cancer cell growth or modulating immune responses. Examples include treatments for cancer, autoimmune diseases, and infectious diseases.

The challenges in antibody drug discovery include:

• Identifying Suitable Targets: Finding the right antigens that are disease-specific and accessible by antibodies.
• Ensuring High Specificity and Affinity: Developing antibodies that specifically bind to the target without affecting healthy cells.
• Reducing Immunogenicity: Engineering antibodies to minimize immune system reactions.
• Optimizing Pharmacokinetics: Enhancing the stability and half-life of antibodies in the body.
• Scaling Up Production: Ensuring consistent quality and efficacy during large-scale manufacturing.

The advantages of therapeutic antibodies include:

• High Specificity: They can precisely target diseased cells without affecting healthy tissues.
• Immune System Engagement: They can recruit the body’s immune system to attack and destroy targeted cells.
• Long Half-Life: They remain active in the body for extended periods, reducing the frequency of administration.
• Fewer Side Effects: Compared to traditional small molecule drugs, antibodies generally have fewer off-target effects.

The limitations include:

• High Production Costs: Manufacturing therapeutic antibodies is expensive and complex.
• Potential for Immunogenicity: There is a risk of the immune system reacting against the antibodies.
• Delivery Challenges: Some tissues are difficult to reach with antibody drugs.
• Complex Manufacturing Processes: Production requires sophisticated facilities and stringent quality control.

Some of the most successful antibody drugs include:

• Trastuzumab (Herceptin): Used to treat HER2-positive breast cancer.
• Adalimumab (Humira): Used for various autoimmune diseases such as rheumatoid arthritis and Crohn’s disease.
• Pembrolizumab (Keytruda): An immunotherapy for various cancers, including melanoma and lung cancer.